We herein observed for the first time that NOTCH1 and JAK2 mutations served as adverse markers affecting outcome (NOTCH1 for EFS and CIR; JAK2 for EFS) in t(8;21) AML. The gene discussed is JAK2; the disease is acute myeloid leukemia.